http://www.onclive.com/conference-coverage/gu-2013/Dr-Cooperberg-on-Earlier-
Treatment-With-Sipuleucel-T
Matthew Cooperberg, MD, MPH
Published Online: Friday, February 15, 2013
Matthew Cooperberg, MD, MPH, Assistant Professor of Urology; Epidemiology & Biostatistics, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses the earlier administration of treatment with sipuleucel-T (Provenge) for men with prostate cancer.
Cooperberg believes that immunotherapies, such as sipuleucel-T, are best administered earlier in the treatment paradigm when the immune system is stronger and less cancer cells are present.
To examine this, a study conducted at the University of California, San Francisco look at the neoadjuvant administration of sipuleucel-T. The primary endpoints for this study were immune parameters that related to immune activation by sipuleucel-T. Cooperberg believes that from a mechanistic standpoint, sipuleucel-T may be most effective when given as a neoadjuvant therapy in prostate cancer.
Treatment-With-Sipuleucel-T
Matthew Cooperberg, MD, MPH
Published Online: Friday, February 15, 2013
Matthew Cooperberg, MD, MPH, Assistant Professor of Urology; Epidemiology & Biostatistics, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses the earlier administration of treatment with sipuleucel-T (Provenge) for men with prostate cancer.
Cooperberg believes that immunotherapies, such as sipuleucel-T, are best administered earlier in the treatment paradigm when the immune system is stronger and less cancer cells are present.
To examine this, a study conducted at the University of California, San Francisco look at the neoadjuvant administration of sipuleucel-T. The primary endpoints for this study were immune parameters that related to immune activation by sipuleucel-T. Cooperberg believes that from a mechanistic standpoint, sipuleucel-T may be most effective when given as a neoadjuvant therapy in prostate cancer.